Differentiation between reactive gliosis and astrocytomas by MIB-1/ki67 immunostaining

Journal of Research in Medical Sciences

Volumn 12, Issue 5, 2007, Pages 241-245

  Mahzouni, Parvin ^a   Mokhtari, Mozhgan ^a   Amirmansour, Bahram ^a  

^a ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Astrocytoma; Gliosis; MIB 1; Monoclonal antibody; Proliferating index

Indexed keywords

KI 67 ANTIGEN; MONOCLONAL ANTIBODY;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; ANALYSIS OF VARIANCE; ANTIGEN EXPRESSION; ARTICLE; ASTROCYTOMA; BRAIN BIOPSY; CANCER GRADING; CHILD; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIFFERENTIAL DIAGNOSIS; FEMALE; FREQUENCY ANALYSIS; GENDER BIAS; GLIOBLASTOMA; GLIOSIS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LABELING INDEX; LINEAR SYSTEM; MAJOR CLINICAL STUDY; MALE; MICROSCOPY; RELIABILITY; SCORING SYSTEM;

EID: 35948984154     PISSN: 17351995     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Prayson RA: The utility of M113-1/Ki-67 inummostaining in the evaluation of central nervous system neoplasms. Adv Anat Pathol 2005, 12: 144-148.
2. Kleihues P, Louis DN, Scheithauer BW, Rorke LB, Reifenberger G, Burger PC et al.: The WHO classification of tumors of the nervous system. J Neuropathol Exp Neurol 2002, 61: 215-225.
3. Davis FG, Kupelian V, Freels S, McCarthy B, Surawicz T: Prevalence estimates for primary brain tumors in the United States by behavior and major histology groups. Neuro Oncol 2001, 3: 152-158.
4. Matsumoto T, Fujii T, Yabe M, Oka K, Hoshi T, Sato K: MIB-1 and p53 immunocytochemistry for differentiating pilocytic astrocytomas and astrocytomas from anaplastic astrocytomas and glioblastomas in children and young adults. Histopathology 1998, 33: 446-452.
5. Colodner KJ, Montana RA, Anthony DC, Folkerth RD, De GU, Feany MB: Proliferative potential of human astrocytes. J Neuropathol Exp Neurol 2005, 64: 163-169.
6. Gerdes J, Schwab U, Lemke H, Stein H: Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation. Int J Cancer 1983, 31: 13-20.
7. Popko B, Pearl DK, Walker DM, Comas TC, Baerwald KD, Burger PC et al.: Molecular markers that identify human astrocytomas and oligodendrogliomas. J Neuropathol Exp Neurol 2002, 61: 329-338.
8. Brown DC, Gatter KC: K167 protein: the immaculate deception? Histopathology 2002, 40: 2-11.
9. Suri VS, Tatke M, Singh D, Sharma A: Histological spectrum of ependyniomas and correlation of p53 and Ki-67 expression with ependymoma grade and subtype. Indian J Cancer 2004, 41: 66-71.
10. Roser F, Samii M, Ostertag H, Bellinzona M: The KI-67 proliferation antigen in meningiomas. Experience in 600 cases. Acta Neurochir (Wien) 2004, 146: 37-44.
11. McLendon RE, Hemdon JE, West B, Reardon D, Wiltshire R, Rasheed BK et al.: Survival analysis of presumptive prognostic markers among oligodendrogliomas. Cancer 2005, 104: 1693-1699.
12. Theunissen PH, Blaauw G: Proliferating cell nuclear antigen immunostaining and survival in cerebral astrocytoma. Histopathology 1993, 23: 75-79.
13. Louis DN, Edgerton S, Thor AD, Hedley-Whyte ET: Proliferating cell nuclear antigen and Ki-67 immunohistochemistry in brain tumors: a comparative study. Acta Neuropathol (Berl) 1991, 81: 675-679.
14. Ariza A, Mate JL, Isamat M, Calatrava A, Fernandez-Vasalo A, Navas-Palacios JJ: Overexpression of Ki-67 and cyclins A and B1 in JC virus-infected cells of progressive multifocal leukoencephalopathy. J Neuropathol Exp Neurol 1998, 57: 226-230.
15. Prayson RA: Cell proliferation and tumors of the central nervous system, part II: radiolabeling, cytometric, and immunohistochemical techniques. J Neuropathol Exp Neurol 2002, 61: 663-672.
16. Bowers DC, Gargan L, Kapur P, Reisch JS, Mulne AF, Shapiro KN et al.: Study of the MIB-1 labeling index as a predictor of tumor progression in pilocytic astrocytomas in children and adolescents. J Clin Oncol 2003, 21: 2968-2973.
17. Dirven CM, Koudstaal J, Mooij JJ, Molenaar WM: The proliferative potential of the pilocytic astrocytoma: the relation between MIB-1 labeling and clinical and neuro-radiological follow-up. J Neurooncol 1998, 37: 9-16.
18. Klein R, Roggendorf W: Increased microglia proliferation separates pilocytic astrocytomas from diffuse astrocytomas: a double labeling study. Acta Neuropathol (Berl) 2001, 101: 245-248.
19. Cummings TJ, Provenzale JM, Hunter SB, Friedman AH, Klintworth GK, Bigner SH et al.: Gliomas of the optic nerve: histological, inmumohistochemical (MIB-1 and p53), and MRI analysis. Acta Neuropathol (Berl) 2000, 99: 563-570.
20. Cunningham JM, Kimmel DW, Scheithauer BW, O'Fallon JR, Novotny PJ, Jenkins RB: Analysis of proliferation markers and p53 expression in gliomas of astrocytic origin: relationships and prognostic value. J Neurosurg 1997, 86: 121-130.
21. Pollack IF, Hamilton RL, Burnham J, Holmes EJ, Finkelstein SD, Sposto R et al.: Impact of proliferation index on outcome in childhood malignant gliomas: results in a multi-institutional cohort. Neurosurgery 2002, 50: 1238-1244.
22. Scott IS, Morris LS, Rushbrook SM, Bird K, Vowler SL, Burnet NG et al.: Immunohistochemical estimation of cell cycle entry and phase distribution in astrocytomas: applications in diagnostic neurepathology. Neuropathol Appl Neurobiol 2005, 31: 455-466.
23. Sallinen PK, Haapasalo HK, Visakorpi T, Helen PT, Rantala IS, Isola JJ et al.: Prognostication of astrocytoma patient survival by Ki-67 (MIB-1), PCNA, and S-phase fraction using archival paraffin-embedded samples. J Pathol 1994, 174: 275-282.